Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585462 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
A Phase 1 study of Cardiometabolic Disease, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 5
- Study locations
NCT06585462 is a Phase 1 study of Cardiometabolic Disease that is actively recruiting participants, run by Amgen. The registered enrollment target is 80 participants. The trial reports 5 study locations across 2 states.
The verdict
NCT06585462, a Phase 1 study of Cardiometabolic Disease, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMG 513
Study Locations (5)
California
- Anaheim Clinical Trials - Anaheim
- Carilion Medical Center - Lake Forest
- Fomat Medical Research - Oxnard
Florida
- Translational Clinical Research LLC - Aventura
- Clinical Pharmacology of Miami, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06585462
The ClinicalTrials.gov registry entry for NCT06585462 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiometabolic Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06585462 reports 5 study locations spanning 2 distinct geographic areas - top geographies include California, Florida.
Frequently Asked Questions
What is clinical trial NCT06585462 about?
NCT06585462 is a clinical study titled "Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity". The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
What is the current status of trial NCT06585462?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-09-09. Estimated completion is 2026-10-01.
What conditions does trial NCT06585462 study?
This clinical trial studies the following conditions: Cardiometabolic Disease.
What interventions are being tested in trial NCT06585462?
The interventions under investigation include: Placebo (DRUG), AMG 513 (DRUG).
Who is sponsoring clinical trial NCT06585462?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585462 being conducted?
This trial has 5 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiometabolic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.